Seer said the PRECISE-SG100K population proteomics initiative will use its Proteograph platform to profile plasma proteomes of about 10,000 participants. The proteomics data will be combined with measurements from Thermo Fisher Scientific’s Olink Reveal and its Orbitrap Astral mass spectrometers, creating a multi-platform dataset for disease-risk and biology research. PRECISE-SG100K is the second phase of a broader Singapore multiomics effort intended to integrate genomic, proteomic, imaging, and lifestyle data across roughly 100,000 residents. Seer said deep, unbiased proteomics is central to scaling the initiative and improving the interpretability of multiomic links to treatment response. The partnership highlights how population biobanks increasingly standardize on vendor ecosystems to generate interoperable clinical-grade biomarker datasets.